Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening
Guardant Health's Shield blood test for colorectal cancer screening will be covered under EviCore by Evernorth clinical guidelines effective January 1, 2027. EviCore is a Cigna-owned company and the second largest specialty benefits manager in the country, serving payers including Blue Cross Blue Shield. Combined with recent coverage expansions from Carelon and UnitedHealth Group, total covered lives for Shield now reach approximately 94 million, which management says represents the overwhelming majority of eligible U.S. patients age 45 and older.
Key figures
- Eligible age
- 45 and older
- Covered lives
- approximately 94 million
- States covered
- 23
- Tests performed
- more than 200,000
- Screening adherence
- over 90%
- Coverage effective date
- January 1, 2027
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.